Cambridge Nucleomics

Cambridge Nucleomics is a biotechnology company developing a proprietary nanopore-based platform for rapid, high-multiplexed detection of nucleic acid biomarkers.

Its enzyme-free soluble nanoarray technology enables simultaneous quantification of up to 200 RNA and DNA targets from low-input samples within one hour. The lead programme targets rapid sepsis diagnosis and antimicrobial resistance profiling directly from whole blood.

Pipeline indications include oncology biomarker profiling, liquid biopsy, and minimal residual disease monitoring.